FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 03:07:27 2024-05-30 am EDT | ||
| 29.2 EUR / 29.26 EUR | +5.83% |
|
| Current month | -2.78% | ||
| 1 month | -3.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 27.62 | -2.40% |
| 24-05-28 | 28.3 | -7.33% |
| 24-05-27 | 30.54 | +0.56% |
| 24-05-24 | 30.37 | -3.00% |
| 24-05-23 | 31.31 | +2.25% |
Delayed Quote Börse Stuttgart
Last update May 29, 2024 at 11:47 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD4ZQ1 |
| ISIN | DE000SD4ZQ16 |
| Date issued | 2021-03-26 |
| Strike | 7,135 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 11.71 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 39.19 € |
|---|---|
| Lowest since issue | 14.66 € |
| Spread | 0.5 € |
| Spread % | 1.78% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
151.7
USD
Average target price
170.2
USD
Spread / Average Target
+12.19%
- Stock Market
- Certificates
- Certificat
